Core Insights - Instinct Science has partnered with Arista Advanced Pet Care to implement its cloud-based practice management platform, Instinct EMR, at Arista's new specialty and emergency hospital in Atlanta, marking a significant milestone for both organizations [1][4]. Company Overview - Instinct Science is a veterinary software company focused on transforming veterinary medicine through advanced practice management software and clinical resources, serving over 360,000 veterinary professionals globally [7]. - Arista Advanced Pet Care is a multispecialty referral and 24/7 emergency veterinary hospital group that aims to revolutionize specialty medicine through a shared ownership model, with plans for national expansion [6]. Product Features - Instinct EMR is designed specifically for the complex workflows of specialty and emergency veterinary hospitals, featuring digital treatment sheets, automated charge capture, administrative tools, and real-time reporting [2]. Partnership Details - The partnership reflects Arista's commitment to building a scalable and efficient foundation for growth while maintaining high standards of patient care and team wellbeing [4]. - Both companies express confidence that the partnership will be mutually beneficial as they expand their operations [5]. Future Plans - Arista's Atlanta facility is the first of many planned hospitals, with expansion into key markets such as Dallas, Texas, anticipated later this year [5].

Core Insights - Vivos Inc. announced that the University of Florida Veterinary Hospital has been certified to offer IsoPet Precision Radionuclide Therapy, a significant advancement in cancer treatment for animals [1][2] - IsoPet therapy is a targeted, minimally invasive treatment that utilizes a proprietary radionuclide injection to address solid tumors in pets, expanding the availability of advanced oncology services [2] Company Strategy - The company aims to expand the network of certified clinics providing IsoPet therapy nationwide, with each certification enhancing access to this effective and less invasive treatment compared to traditional options [3] - Vivos Inc. supports clinics through the licensing process and provides necessary training to ensure safe and effective administration of IsoPet therapy [3] Market Position - The University of Florida Veterinary Hospital is recognized as a leader in advanced veterinary care and research, indicating a strong market position for the newly certified IsoPet therapy [2]

Financial Data and Key Metrics Changes - Overall revenues increased by 5% organically, with a 4.5% organic growth in CAG Diagnostic recurring revenues, despite a 1.5% headwind from equivalent days [4][5] - EPS was $2.96 per share, reflecting a 5% growth as reported and 7% growth on a comparable basis [5][17] - Gross profit increased by 5% as reported and 6% on a comparable basis, with gross margins at 62.4%, up 80 basis points on a comparable basis [15][17] Business Line Data and Key Metrics Changes - CAG organic revenue growth was supported by 7% organic gains in veterinary software and diagnostic imaging revenues, while CAG instrument revenues decreased by 5% organically [6][7] - Water revenues increased by 7% organically, driven by double-digit revenue expansion in Europe [14] - Global rapid assay revenues declined by 2% organically, constrained by customers shifting pancreatic lipase testing to the Catalyst instrument platform [12] Market Data and Key Metrics Changes - U.S. CAG Diagnostic recurring revenue organic growth was 3% in Q1, reflecting a solid growth premium compared to a 2.6% decline in U.S. clinical visits [8][9] - International CAG Diagnostic recurring revenue organic growth was 8.5%, with strong volume gains building on 2024 momentum [8] - IDEXX VetLab consumable revenues increased by 10% organically, supported by a 9% year-over-year growth in the global premium instrument installed base [10] Company Strategy and Development Direction - The company is focused on innovation, highlighted by the launch of IDEXX CancerDx for canine lymphoma and the rollout of IDEXX InVue DX, a new cellular analyzer [24][26] - IDEXX aims to maintain solid organic revenue growth and comparable operating margin improvement, with updated guidance reflecting positive changes from foreign exchange [18][19] - The company is well-positioned to navigate the changing tariff landscape, with 65% of consolidated revenues from the U.S. and less than 1% from China [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term growth potential, despite macroeconomic pressures affecting clinical visits [6][38] - The estimated pet population remained stable, supporting strong tailwinds for the business and confidence in delivering solid organic revenue growth [39] - Management noted that while clinical visit metrics are under pressure, diagnostic frequency and utilization remain strong drivers for the business [62] Other Important Information - The company updated its full-year guidance for reported revenues to $4.095 billion to $4.210 billion, reflecting a $40 million increase related to foreign exchange [19] - Free cash flow was $208 million in Q1, with a trailing twelve-month net income to free cash flow conversion ratio of 95% [17] - Share repurchases during the first quarter totaled $415 million, supporting a 2.4% reduction in diluted shares outstanding [18] Q&A Session Summary Question: Can you discuss the trends in clinical visits and the macro environment? - Management noted a consistent trend in wellness and non-wellness visits, with some optimism that clinical visit moderation has stabilized [46][48] Question: What feedback have you received regarding the IDEXX InVue DX? - Initial feedback has been positive, with customers enthusiastic about the ease of use and accuracy of results [52][56] Question: How is the company positioned regarding tariffs and potential impacts? - The company is relatively well-positioned with a majority of revenues from the U.S. and has operational plans to mitigate tariff impacts [65][68] Question: Can you provide insights on the uptake of CancerDx? - Over a thousand unique practices have ordered the test, indicating strong initial interest and awareness [73][75] Question: What gives you confidence in the guidance for CAG recurring revenue? - Management expects clinical visits to decline similarly to 2024 levels, with ongoing innovations supporting growth [78][80]

Financial Data and Key Metrics Changes - Overall revenues increased by 5% organically, with a 4.5% organic growth in CAG Diagnostic recurring revenues, despite a 1.5% headwind from equivalent days [4][5] - EPS was $2.96 per share, reflecting a 5% growth as reported and 7% growth on a comparable basis [5][18] - Gross profit increased by 5% as reported and 6% on a comparable basis, with gross margins at 62.4%, up 80 basis points on a comparable basis [16][18] Business Line Data and Key Metrics Changes - CAG organic revenue growth was supported by 7% organic gains in veterinary software and diagnostic imaging revenues, while CAG instrument revenues decreased by 5% organically [6][7] - Water revenues increased by 7% organically, driven by double-digit revenue expansion in Europe [15] - Global rapid assay revenues declined by 2% organically, constrained by customers shifting pancreatic lipase testing to the Catalyst instrument platform [13] Market Data and Key Metrics Changes - International CAG Diagnostic recurring revenue organic growth was 8.5%, reflecting strong volume gains and net price realization [9] - U.S. CAG Diagnostic recurring revenue organic growth was 3% in Q1, net of days headwind, compared to a 2.6% decline in U.S. clinical visits [10][9] - The estimated pet population sustained in 2024 at similar levels to the prior year, supporting strong tailwinds for the business [40] Company Strategy and Development Direction - The company is focused on innovation, highlighted by the launch of IDEXX CancerDx for canine lymphoma and IDEXX InVue DX, a new cellular analyzer [26][34] - The strategy includes expanding the oncology menu to address the majority of canine cancer cases within three years [33] - The company aims to maintain a strong commercial model grounded in partnership, flexibility, and execution excellence to drive innovation-led growth [31] Management's Comments on Operating Environment and Future Outlook - Management noted that macroeconomic conditions remain dynamic, but there are strong demand signals and continued willingness by clinics to invest in diagnostics [31][39] - The company is well-positioned to navigate the changing tariff landscape, with 65% of revenues based in the U.S. and minimal exposure to China [38][63] - Management expressed optimism about the stabilization of clinical visit moderation and the potential for growth in diagnostic frequency and utilization [47][61] Other Important Information - The company updated its full-year guidance for reported revenues to $4.095 billion to $4.210 billion, reflecting a $40 million increase related to foreign exchange [21] - The updated full-year EPS outlook is $11.93 to $12.43 per share, driven by foreign exchange and favorable adjustments [23] - Free cash flow was $208 million in Q1, with a trailing twelve-month net income to free cash flow conversion ratio of 95% [18] Q&A Session Summary Question: Can you discuss the trends in clinical visits and macroeconomic conditions? - Management noted a consistent trend in wellness and non-wellness visits, with some optimism about stabilization despite macro headwinds [46][47] Question: What feedback has been received regarding the IDEXX InVue DX? - Initial feedback has been positive, with customers enthusiastic about the ease of use and accuracy of results, leading to a significant ramp-up in placements [50][52] Question: How is the company positioned regarding tariffs and potential impacts? - The company is relatively well-positioned with a majority of revenues from the U.S. and has operational plans in place to mitigate tariff impacts [63][64]

Financial Data and Key Metrics Changes - Revenue increased by 6% organically in Q4 2024, with CAG Diagnostic recurring revenues growing by 7% organically [4][5] - Operating profits rose by 7% as reported and 8% on a comparable basis, with EPS reaching $2.62, up 10% on a comparable basis [5][20] - Full year EPS was $10.67, a 12% increase on a comparable basis, despite a $0.56 per share negative impact from litigation expenses [7][21] Business Line Data and Key Metrics Changes - CAG Diagnostic recurring revenue increased by 7% organically in Q4, with U.S. volume growth normalized for equivalent selling days at approximately 2% [8][10] - Water business saw 11% organic growth for the full year, while global premium instrument installed base grew by 9% [5][6] - IDEXX VetLab consumable revenues increased by 12% organically, supported by a 9% increase in the global premium instrument installed base [13][19] Market Data and Key Metrics Changes - International CAG Diagnostic recurring revenue growth was 12% in Q4, benefiting from net price gains and improved volume growth [12] - U.S. clinical visit levels declined nearly 3% in Q4, reflecting transitional sector impacts post-pandemic [11][12] - The company achieved a solid 800 basis point normalized growth premium compared to U.S. clinical visit growth levels in Q4 [11] Company Strategy and Development Direction - The company is focused on innovation-driven growth, with new product launches such as IDEXX InViewDx and IDEXX CancerDx aimed at enhancing diagnostic capabilities [31][44] - IDEXX plans to continue expanding its international footprint, with double-digit growth in premium installed base outside the U.S. [38][39] - The strategy includes leveraging software solutions to enhance clinic efficiency and deepen customer relationships, as seen with the Velo application [45][46] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing pressure on U.S. clinical visits but noted strong demand for higher standards of pet care [35][36] - The outlook for 2025 includes projected revenue growth of 4% to 7% on a reported basis, with organic growth expectations of 6% to 9% [23][24] - Management expressed confidence in the company's growth potential, supported by strong execution and innovation [80] Other Important Information - The company plans to allocate $1.5 billion towards share repurchases, reflecting confidence in growth potential [28][80] - Capital spending for 2024 was $121 million, approximately 3% of revenue, with free cash flow at $808 million [22][21] Q&A Session Summary Question: Can you speak to what guidance assumes now in terms of the innovation contribution in 2025? - Management indicated that the guidance includes approximately $50 million and 4,500 placements from the InViewDx platform, with additional benefits expected from other innovations [55][56] Question: What led to the uptick for the premium in Q4? - The increase was attributed to strong consumable growth and progress in instrument placements, reflecting strong execution throughout the year [84][85] Question: Can you elaborate on the vet visit trajectory expected from here? - Management expects a similar decline in clinical visits as seen in 2024, with approximately 2% decline anticipated for 2025 [68] Question: What is the rationale for the increased share buyback? - The rationale is based on high confidence in the company's growth model and strong free cash flow generation, allowing for a higher deployment rate [80] Question: Are you still limiting preorders for InViewDx? - Management confirmed that preorders have been opened in North America, while international preorders remain limited [93] Question: Was there any impact from weather on visit trends for Q4? - Weather impacts were noted, but management feels confident in the guidance provided despite these factors [95]

As filed with the Securities and Exchange Commission on July 1, 2024. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) 780 Lynnhaven Parkway Suite 400 Virginia Beach, V ...

As filed with the Securities and Exchange Commission on June 21, 2024. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) 780 Lynnhaven Parkway Suite 400 Virginia Beach, ...

As filed with the Securities and Exchange Commission on June 13, 2024. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) Nevada 8900 85-4359258 780 Lynnhaven Parkway Suite 400 Virginia Beach, Virginia 23452 Telephone: (757) 734-5464 (Address, Including Zip Code, and Telephone Number, Including Area C ...

As filed with the Securities and Exchange Commission on February 9, 2024. Registration No. 333-276790 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 8900 85-4359258 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identificat ...

As filed with the Securities and Exchange Commission on January 31, 2024. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRE VETERINARY PARTNERS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) Nevada 8900 85-4359258 780 Lynnhaven Parkway Suite 400 Virgin ...